NOTCH1 and acute lymphoblastic leukemia: The therapies for T-ALL have improved in recent years, and these include several inhibitors that target molecules that are essential for Notch1 signaling, such as γ‐secretase inhibitors, ADAM inhibitors, SERCA inhibitors, and monoclonal antibodies that target Notch138.